Comments
Alkem Laboratories has entered into an agreement with AbbVie Inc, US, for acquisition of certain assets related to API Dronabinol for $10 million, plus working capital, on closing of the deal. The assets include domain names and trademarks related to Marinol, a new drug application registration with the USFDA for Marinol, logos, patents, designs, know how, technical and manufacturing instructions, inventory, and manufacturing equipment, among others. The company will own the NDA and associated assets and will use these to commercially exploit both branded and generic sales in the US. Shares of Alkem Laboratoriess jumped 1.21 per cent at ₹2013.55 on the BSE
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.